Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.
Sorscher SM, Lockhart AC. Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma. J Clin Oncol. 2011 Jul 01; 29(19):2735-6; author reply 2736-8.